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Abstract  
Alzheimer’s disease (AD) is characterized by memory loss, insidious cognitive decline, profound 
neurodegeneration and the extracellular accumulation of amyloid-beta (Aβ) peptide in senile 
plaques and intracellular accumulation of tau in neurofibrillary tangles. Loss and dysfunction of 
synapses are believed to underlie the devastating cognitive decline in AD.  A large amount of 
evidence suggests that oligomeric forms of Aβ associated with senile plaques are toxic to 
synapses, but the precise sub-synaptic localization of Aβ and which forms are synaptotoxic 
remain unknown. Here, we characterize the sub-synaptic localization of Aβ oligomers using 
three high-resolution imaging techniques, stochastic optical reconstruction microscopy, 
immunogold electron microscopy and Förster resonance energy transfer in a plaque-bearing 
mouse model of Alzheimer’s disease. With all three techniques, we observe oligomeric Aβ inside 
synaptic terminals. Further, we tested a panel of Aβ antibodies using the relatively high-
throughput array tomography technique to determine which forms are present in synapses. Our 
results show that different oligomeric Aβ species are present in synapses and highlight the 
potential of array tomography for rapid testing of aggregation state specific Aβ antibodies in 
brain tissue. 
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Introduction 
Alzheimer’s disease (AD) is a devastating neurodegenerative disease associated with profound 
cognitive decline and memory dysfunction. Pathologically, the brains of patients are 
characterized by the presence of aggregated amyloid-beta (Aβ) in senile plaques, the 
intracellular accumulation of hyperphosphorylated tau in neurofibrillary tangles, and brain 
atrophy due to loss of neurons and synapses [1]. Of these pathological changes in AD brain, 
decreased connectivity between neurons due to synapse loss correlates most strongly with 
cognitive decline.  
 
A large body of evidence supports a role for soluble amyloid-beta (Aβ)  in synapse dysfunction 
and collapse [2-6]. Aβ, particularly in oligomeric form, facilitates long-term depression and 
inhibits long-term potentiation, both electrophysiological correlates of memory formation [7-9]. 
Whether Aβ induces synapse loss directly by interaction with synaptic receptors or indirectly 
through interactions with intermediate molecules is not clear, it is therefore necessary to study 
these interactions at the synaptic level. However, synapses are too small to be visualized 
accurately using traditional light microscopy (including multiphoton and confocal imaging) due to 
the limitation of the axial (z) resolution. The array tomography technique developed by Micheva 
and Smith [10, 11] overcomes the z resolution limit by physically cutting fixed tissue samples 
into 70 nm serial sections. This enables the visualization of synapses and proteins of interest 
using standard immunofluorescence techniques. Using the oligomer-recognizing Aβ antibody 
NAB61 [12] on tissue prepared for array tomography, we previously demonstrated that 
oligomeric Aβ (oAβ) accumulates in a halo around the edges of plaques and colocalizes with a 
subset of synapses in wild-type and APPswe/PS1deltaE9 mice [13]. We further pioneered the 
use of array tomography for human postmortem tissue [14] and found that in human AD brain, 
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oAβ is associated with a subset of small synapses near plaques, confirming the relevance of this 
pathway to human disease [15]. 
 
Since the association of oAβ with synapses occurs most often in the halo of oligomers 
surrounding plaques, we assume that the synaptic oAβ derives from extracellular sources and 
binds to receptors in the synaptic cleft. Thus we expected that oAβ would bind the extracellular 
face of the pre and postsynaptic terminals, although data have been presented indicating that 
oAβ can enter cells through several mechanisms including direct permeabilization of the 
membrane by oAβ [16] and endocytosis [17]. The resolution of array tomography imaged with 
standard fluorescent microscopy is approximately 250 nm in the x-y plane, which does not allow 
accurate determination of whether oAβ is found in the synaptic cleft or within synapses with 
standard imaging techniques. Here we have examined whether NAB61-positive Aβ oligomers 
are found in the synaptic cleft or within the postsynapse using three high resolution imaging 
techniques: stochastic optical reconstruction microscopy (STORM), immunogold transmission 
electron microscopy (TEM), combined array tomography and Förster resonance energy transfer 
(FRET) imaging. All of these techniques indicate that oAβ is present within the postsynapse and 
further validate the use of array tomography for accurate localization of pathological proteins 
with synapses. 
Following the validation of the array tomography technique for accurate colocalization of oAβ at 
synapses, we tested a panel of Aβ antibodies: the previously characterized monoclonal 
aggregate-preferring oAβ antibody (NAB61) which recognizes oligomers and fibrils but not 
monomers [12], a monoclonal aggregate-selective antibody (1C22) [18], a conformation-specific 
antibody known to detect fibrillar oAβ arranged in in-register parallel β sheets (OC) [19-21] and a 
polyclonal anti-Aβ antibody (AW7) which recognises multiple Aβ assemblies and epitopes, 
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including monomeric Aβ40 and Aβ42 [22]. We explore to what extent these antibodies bind oAβ 
and recognise synapse-associated oAβ. Applying this array tomography approach in a 
transgenic AD mouse model (APP/PS1), we demonstrate that all four Aβ antibodies co-localize 
with a subset of postsynaptic densities and a subset of presynapses around plaques in 
APP/PS1 brain.  
 
This study illustrates the power of array tomography for detecting pathological protein 
conformations at individual synapses, and confirms with multiple antibody probes that oAβ is 
present in synapses in a mouse model of AD.  
 
Material and Methods 
Animals 
Brains from APP/PS1 (n=9) and wild-type (n=4) mice aged 8-12 months were used in this study. 
At this age, APP/PS1 mice have discernible deficits in spatial reference memory [23], substantial 
plaque pathology and well-established plaque associated synapse loss and synaptic Aβ 
accumulation [13, 24]. All animal experiments were performed in accordance with institutional 
and national ethics guidelines and approved by the Harvard Medical School Institutional Animal 
Care and Use Committee and the UK Home Office.  
 
STORM 
Ultra-thin sections (70 nm) of APP/PS1 mouse brains were prepared from array tomography-
embedded blocks as described below. Slides were incubated in fresh 0.1% (w/v) sodium 
borohydride (NaBH4) in PBS for 7 minutes to quench autofluorescence, blocked in 5% goat 
serum in PBS for 30 minutes, immunolabeled for PSD and oAβ (Table 1), and then post-fixed 
with 3% paraformaldehyde and 0.1% glutaraledehyde in PBS. Immunolabeling was done using 
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goat anti-PSD95 and then donkey anti-goat Alexa488 and for oAβ using NAB61 (dilution 1:20) 
and then 3 mg/ml goat anti-mouse antibody (Jackson) labeled with a Cy3 (activator 
dye)/Alexa647 (reporter dye) photo-switch dye pair for STORM (labeling ratios 
[antibody:activator:reporter] were [1:1.8:3.7]). Conventional fluorescence imaging of PSD95-
Alexa488 and NAB61-Cy3 allowed initial localization of synaptic terminals and amyloid plaques. 
After bleaching autofluorescence of the tissue with epifluorescent light for 5 minutes, subsequent 
STORM imaging of NAB61-Cy3-Alexa647 revealed the precise localization of oAβ. STORM 
imaging buffer (10 mM Tris-HCl pH8.0, 10 mM NaCl, 10% sucrose) contained 1% 2-
Mercaptoethanol (Sigma), 34 mg/ml catalase, and 700 mg/ml sucrose oxidase to prevent dye 
bleaching and enable efficient photo-switching between bright and dark state of the reporter dye. 
 
STORM data acquisition was performed with a 100x oil immersion objective (Plan Apo VC 100x 
1.4 oil) using a N-STORM microscope system (Nikon) equipped with perfect focus system, TIRF 
laser line for plane illumination, and an EM-CCD camera. To reduce the out-of-focus 
fluorescence, samples were first illuminated with 647 nm imaging laser at low intensity (laser 
power 1.5 mW), actual imaging cycles contained one frame of 561 nm activation laser (laser 
power ~0.03 mW) to activate a small fraction of reporter fluorophores followed by 3 frames of 
647 nm imaging laser illumination (laser power ~150 mW). A total of 15000 frames were 
collected at 33 frames per second. STORM data was analyzed with ElementsV (Nikon) applying 
drift compensation, and allowing for a signal duration of 30 ms and a minimum of 500 photons 
counted per pixel (camera sensitivity = 0.18 photons per count). 
 
Immunogold-TEM 
Four APP/PS1 mice were perfused with PBS containing 4% paraformaldehyde and 0.1% 
glutaraldehyde, then their brains were dissected and stored in the same buffer at 4°C for 48 
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hours to complete fixation. 100 µm thick vibratome sections were prepared from these brains 
and cut into small blocks containing sensory cortex.  Tissue blocks were post-fixed in 0.1% 
osmium tetroxide for 1 hour, then dehydrated through a series of graded ethanols, transferred 
into propylene oxide, and embedded in araldite/DDSA (dodecyl succinic anhydride) resin with 
benzyldimethylamine (BDMA) catalyst according to manufacturer instructions (Electron 
Microscopy Sciences EMS, Hatfield PA USA). 70 nm thick sections were cut on a Leica Ultracut 
microtome and floated onto formvar carbon-coated nickel EM grids (EMS).  Sections were 
treated with saturated sodium metaperiodate in water for 1 minute to remove excess osmium, 
and treated for 5 minutes with 1% sodium borohydride and rinsed with 50 mM glycine in PBS to 
reduce free aldehyde groups. EM grids were incubated in blocking buffer for donkey secondary 
antibodies (Aurion, EMS) for 30 minutes, then in PBS containing 0.2% BSA and primary 
antibody NAB61 (Table 1) in a 1:20 dilution for 2 hours at room temperature.  Grids were 
washed in PBS for 5 minutes 6-times and then incubated in PBS containing 0.2% BSA and 
immunogold-conjugated donkey anti-mouse 15 nm gold conjugate (dilution 1:50, EMS) for 1.5 
hours. Sections were washed in PBS as before, post-fixed in PBS containing 2.5% 
glutaraldehyde, and counter stained with 3% uranyl acetate in 50% ethanol for 15 minutes 
followed by 4% lead citrate in a CO2 free environment for 2.5 minutes.  EM grids were imaged 
using a JEOL JEM-1011 transmission electron microscope with Hamamatsu ORCA digital 
camera (courtesy Marian DiFiglia and the Philly Dake Electron microscopy core).  Synapses 
were defined by an electron dense postsynaptic density adjacent to a presynaptic terminal 
containing at least 3 synaptic vesicles.  Apposition length was measured along the distance of 
the PSD facing the synaptic cleft of type 1 (putative excitatory) synapses. 
 
FRET microscopy 
For acceptor photobleaching FRET analysis [25] of NAB61 and postsynaptic marker PSD95 
colocalization, array ribbons from APP/PS1 (n=5) and wild-type (n=4) mice were 
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immunofluorescently labeled for oAβ using NAB61 and donkey anti-mouse Cy5 (acceptor 
secondary antibody) and for PSD using goat anti-PSD95 and rabbit anti-goat Cy3 (donor 
secondary antibody) as described previously [13, 15].  Briefly, array ribbons were rehydrated for 
5 minutes in 50 mM glycine in 1X Tris-buffered saline (TBS) and placed in blocking buffer 
(0.05% Tween and 0.1% BSA in TBS) for 30 minutes. Ribbons were immunostained with 
primary antibodies against NAB61 and PSD95 (Table 1) overnight at 4°C. The following day 
sections were washed five times in TBS before fluorescently labeled secondary antibodies were 
applied at a 1:50 dilution in blocking buffer for 30 minutes.  Sections labeled only with 
PSD95+Cy3 but no NAB61 were used as negative controls. Sections triple labeled for PSD 
using goat anti-PSD95 as primary, rabbit anti-goat Cy3 as secondary, and donkey anti-rabbit 
Cy5 as tertiary antibodies functioned as positive controls. Images were taken with a 63x 1.4NA 
oil objective at excitation wavelengths of 543 nm and 633 nm (~50% laser power, PMT voltages 
~625 V) using a Leica confocal microscope equipped with a FRET module (Leica TCS SL). For 
each field of view, an initial image of Cy3 and Cy5 (PSD and NAB61) fluorescence was 
acquired, then the Cy5 acceptor fluorophore was bleached at 100% laser power at 633 nm.  
After bleaching, a second image of the same sample area was obtained using identical settings 
as for the image taken before bleaching.  For image analysis, regions of interest (ROIs) were 
drawn around PSD95-positive punctae in the pre-bleach image. FRET efficiency, FRETeff, was 
calculated from Cy3-donor fluorescence intensity before, Dpre, and after, Dpost, as FRETeff = 
(Dpost-Dpre)/Dpost for each ROI showing Dpost>Dpre. Synapses were considered NAB61-
positive if the Cy5-acceptor fluorescence intensity before bleaching was at least 3-times higher 
than the Cy5 background fluorescence in the same ROI after bleaching.  
 
Array tomography 
Fresh brain tissue samples were collected from APP/PS1 transgenic mice as outlined previously 
[13, 14]. Briefly, small tissue blocks of four 8-12 month old APP/PS1 mice were fixed in 4% 
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paraformaldehyde and 2.5% sucrose in 20 mM phosphate buffered saline pH7.4 (PBS) for 3 
hours. Samples were then dehydrated through ascending cold graded ethanol and embedded 
into LR White resin (EMS) which was allowed to polymerize overnight at 53°C. Resin embedded 
tissue blocks were cut into array ribbons of 70 nm thick sections using an ultracut microtome 
(Leica) equipped with a Jumbo Histo Diamond Knife (Diatome, Hatfield, PA) and collected onto 
gelatin coated coverslips.  
 
For immunolabeling of synapses and Aβ on “day 1”, array ribbons were immunostained as 
described for FRET imaging with primary antibodies against NAB61 and PSD95 (Table 1) and 
fluorescently labeled secondary antibodies (Table 1). Sections were counterstained with 
0.01mg/mL 4’-6-diamidino-2-phenylindole (DAPI). For each area of interest, images were 
obtained on serial sections using a Zeiss axio Imager Z2 epifluorescent microscope at 63X 
1.4NA Plan Apochromat objective with equipped CoolSnap digital camera and AxioImager 
software with array tomography macros (Carl Zeiss, Ltd, Cambridge UK).  
 
Coverslips were removed from slides and washed. All primary and secondary antibodies were 
stripped for 15 minutes using stripping buffer (0.2 M NaOH 0.02% SDS in ddH20). The staining 
protocol was repeated as previously described for “day 1” with primary antibodies against 1C22, 
OC and PSD95 and appropriate secondary antibodies (Table 1). Images were captured in the 
same location as the previous day using identifiable marked nuclei. Following “day 2” imaging 
the ribbons were once again stripped of all antibodies and stained with antibodies against AW7 
and Synaptophysin for “day 3” (Table 1). Images were obtained in the same location as both 
days 1 and 2 using specific nuclei as markers. Images from each set of serial sections across 
the three days were converted into image stacks and aligned using the Image J plug-in, 
MultiStackReg (courtesy of Brad Busse and P. Thevenaz, Stanford University) [26]. Cropped 
regions of interest (10 µm2) around the plaque were generated. Amyloid-beta image stacks were 
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then binarised using thresholding algorithms in ImageJ. For synaptic images stacks were 
binarised using an ImageJ script that combines different thresholding algorithms in order to 
select both high and low intensity synapses in an automated and unbiased manner.  
Thresholded images were processed and analysed in MATLAB to remove background noise 
(objects present in only a single section were removed) and to calculate the colocalization of Aβ 
with both pre- and post-synapses. The % colocalization for each antibody combination from 
each mouse was calculated as the sum of the number of colocalization/sum total pre- or post-
synapses.  
 
Statistical analyses 
FRET: From a total of 3462 NAB61-negative and 105 NAB61-positive synapses across the 9 
imaged animals (5x APP/PS1, 4x wild-type mice), the mean FRET efficiencies of NAB61-
negative, NAB61-positive, positive control, and negative control synapses were calculated for 
each animal.  Significance of variance between mouse genotypes and between the presence 
and absence of NAB61 at synapses were tested using two-way ANOVA analysis (with SPSS 
software, SAS).  Data are presented as mean and standard error. 
Array Tomography: Data for each colocalization combination between the four mice was not 
normally distributed so the non-parametric Kruskal-Wallis test was performed with Dunn’s post-
hoc comparisons (GraphPad Prism 4). All values are reported as median and interquartile 
range. 
 
Data Sharing: 
Upon acceptance, all data used in this manuscript including custom image analysis scripts for 
ImageJ and MATLAB will be freely shared on the University of Edinburgh Data Repository 
http://datashare.is.ed.ac.uk. 
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Results 
STORM, TEM and FRET confirm presence of oAβ  in the postsynaptic density  
We have previously shown that oAβ recognised by NAB61 is associated with synaptic 
degeneration in the APP/PS1 mouse model and human AD patient brain [13, 15]. Here, we 
further specified the localization of these oAβ species applying several high-resolution imaging 
techniques. STORM was used to determine the localization of oAβ with respect to PSDs with 
nanometer precision on array tomography 70 nm sections. After imaging of immunofluorescently 
labeled PSD and oAβ in ultra-thin sections with conventional epifluorescence, which allowed the 
initial localization of synapses and the identification of amyloid plaques in the brain, STORM 
imaging of NAB61 revealed the precise localization of Aβ oligomers in the neuropil surrounding 
plaques. Overlaying the NAB61−STORM images with the corresponding PSD95-epifluorescence 
images showed a clear co-localization of oAβ  with a subset of PSDs in APP/PS1 mouse brain 
(Figure 1A-B).   
 
Immunogold labeling of NAB61 in APP/PS1 brain samples observed with TEM was used to 
determine further the precise subcellular localization of oAβ.  We observe the most robust 
NAB61 staining in close proximity to plaque fibrils (Figure 1C and Supplemental Figure 1) as 
expected from the intense plaque labeling with NAB61 in immunofluorescence studies. We also 
observed NAB61 immunogold labeling in both presynaptic and postsynaptic terminals (Figure 
1C) confirming our immunofluorescence data showing NAB61 colocalization with synaptic 
staining in the neuropil. Notably, in synapses, the oAβ was not associated with fibrils, which are 
readily recognized by TEM (Figure 1C).  None of the synapses observed across 4 mice 
(regardless of whether they were positive for NAB61) contained fibrils. This provides additional 
confirmation of the previous NAB61 characterization [12] as recognising oligomeric Aβ in 
addition to our observed fibril staining. NAB61 staining was not restricted to plaques and 
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synapses.  We also observe staining in cell bodies, dendrites, and mitochondria (Supplemental 
Figure 2), which supports our array tomography immunofluorescence observations of NAB61 in 
some neuronal cell bodies and in punctae in the neuropil that are not positive for synaptic 
markers [13, 15].  
 
To determine whether oAβ is present inside PSDs, as indicated by colocalization with PSD95 
punctae in array tomography sections, we performed FRET microscopy on these sections, which 
allows the detection of two fluorophores in close (<10 nm) proximity. After labeling PSDs with 
antibody PSD95 and donor fluorophore (Cy3) labeled secondary antibody and labeling oAβ with 
NAB61 and acceptor fluorophore (Cy5) labeled secondary antibody, we performed confocal 
microscopy of the brain sections before and after bleaching the acceptor (Figure 2). The 
average FRET efficiency of NAB61-positive synapses in APP/PS1 mice (5.3%) was 
approximately 3-fold increased compared to NAB61-negative synapses (1.9% FRET efficiency). 
Similarly, the rare synapses that were NAB61 positive in wild-type also had increased FRET 
efficiency with PSD95 (5.2%) compared to NAB61 negative synapses (1.7%). Two way ANOVA 
analysis reveals a significant increase in FRET efficiency in NAB61 positive synapses (F=5.6, 
p=0.04). The FRET efficiency of NAB61-negative synapses was similar to the negative control 
FRET efficiency in which there was no acceptor fluorophores (2.1%). Positive control labeling of 
PSD95 with both donor and acceptor fluorophores (with a Cy3 labeled secondary antibody and 
Cy5 labeled tertiary antibody) had an average FRET efficiency of 25%, which is ceiling for our 
experiment. No difference in FRET efficiency was detected between synapses of wild-type and 
APP/PS1 mice (two-way ANOVA F=0.002, p=0.962).  There was no interaction between 
genotype and NAB61 status (F=0.002, p=0.962), indicating the labelled fluorophores are within 
10 nm and due to the distance added by antibody labelling, we estimate that oAβ is within at 
most 10-30 nm of PSDs in both genotypes. 
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Array tomography reveals synaptic staining with several markers of Aβ  
To characterize the synaptic profile of four Aβ-specific antibodies; NAB61, 1C22, OC and AW7, 
we immunolabeled Aβ and synaptic markers in array tomography sections of APP/PS1 mouse 
brains (n=4 mice) in a three-day imaging protocol (Figure 3). In each experiment, a small extra 
ribbon of sections was used as a stripping control with no primary antibodies applied on the 
subsequent day. Applying secondary antibodies after stripping confirmed effective stripping of 
antibodies on each day of staining (Supplemental Figure 3). 
 
We found that all four antibodies labeled plaques in APP/PS1 brains (Figure 4A-D). To 
determine whether and to what extent oAβ colocalizes with synapses, we applied combinations 
of PSD recognizing antibody (PSD95), presynaptic recognizing antibody (synaptophysin) and 
the different Aβ antibodies (Figure 4 and Figure 5). Across four APP/PS1 mice, subsets of PSD-
positive synaptic punctae (n=6,548) colocalized with Aβ labeling by NAB61 (9.8% of synaptic 
punctae), 1C22 (15.9%), AW7 (17.3%) and OC (24.1%) (Figure 6A).  Dunn’s post-hoc analysis 
revealed a significant difference between the percentages of NAB61 positive postsynaptic 
punctae and OC positive postsynaptic punctae (p<0.05). Interestingly, colocalization between 
two Aβ detecting antibodies and PSD95 was observed in a subset of synapses with the highest 
% colocalization between AW7 + OC (12.3%) and 1C22 + OC (11.5%) (Figure 6B).  Further 
analysis revealed a subset of postsynapses colocalized with all four antibodies (5.0%). 
Presynaptic staining revealed a subset of synaptophysin-positive synaptic punctae (n=5,573) 
colocalized with Aβ stained with NAB61 (8.1% of synaptic punctae), 1C22 (11.6%), AW7 
(14.3%) and OC (18.9%) (Figure 6A). Dunn’s post-hoc analysis revealed a significant difference 
between the percentages of NAB61 positive presynaptic punctae and OC positive presynaptic 
punctae (p<0.05). In addition, a subset of presynapses colocalized with two Aβ detecting 
antibodies with the highest % colocalization observed again between combinations of AW7 + 
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OC (9.0%) and 1C22 + OC (7.8%) (Figure 6C).  A subset of presynapses colocalized with three 
Aβ detecting antibodies and a smaller subset colocalized with all four antibodies (4.0%). These 
data show that multiple antibodies confirm the presence of oligomeric Aβ in synapses. Further, 
each of the Aβ antibodies used recognises different confirmations ranging from monomeric Aβ, 
fibrillar oligomers and fibrils.  Since not all synapses containing Aβ are recognized by all of these 
antibodies and we do not observe fibrils in synapses by EM, we conclude that there are likely 
multiple forms of soluble Aβ present in synapses.  These data further highlight the utility of this 
technique for measuring synaptic localization of pathological epitopes of proteins. 
 
Discussion 
There is mounting evidence that oAβ plays a key role in synapse dysfunction and loss [27]. 
Oligomeric Aβ modulates several intracellular pathways including activating caspase-3 and 
calcineurin at the synapse to ultimately culminate in synaptic failure [28-31]. Synaptic 
dysfunction may precede cognitive decline in AD by several decades and could potentially be 
reversible [32].  In this study, we addressed two important remaining questions around 
oAβ−mediated synapse loss, namely is toxic oAβ located in the synaptic cleft or within 
presynaptic terminals and postsynaptic densities? And which forms of Aβ are associated with 
synapses? 
 
Whether toxic Aβ at synapses originates from intracellular or extracellular sources is a hotly 
debated topic in the field [33-36]. Here we used three high-resolution imaging techniques to 
examine whether oAβ is present within synaptic terminals or decorating the exterior membrane 
of pre and postsynapses and find that NAB61 labeled oAβ is present inside synapses. Our data 
suggest that synaptotoxic oAβ derives from the extracellular plaque halo since localization of Aβ 
at synapses occurs most often in this region [13, 15], however it appears oAβ is present within 
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synapses (Figures 1-2). This could occur alongside the internalization of synaptic receptors 
initiated by oAβ or more directly through the reported pores that Aβ can form in membranes [27, 
37].  It is also worth noting, that while we specifically examined synapses in this study, we did 
observe oAβ in other subcellular compartments by TEM.  We observed immunogold labelling 
associated with ribosomes in neuronal somata and dendrites, cell membrane staining, and 
mitochondrial staining (Supplemental Figure 2).  Mitochondrial staining is particularly interesting 
in light of the large body of literature supporting a role of oAβ in causing mitochondrial damage 
[38] 
 
Another contentious and important topic on the road to synapse-directed therapeutics is which 
specific forms of oAβ are toxic at synapses and therefore which would be the best targets. One 
recent study in mice classified oligomers in mice as type 1 (A11-immunoreactive, Aβ*56) and 
type 2 (recognized by OC) and concluded that type 2 oligomers were less toxic because of their 
containment within plaques [21]. Our data indicate that type 2 oligomers (OC positive) are 
present in synapses, where they may contribute to toxicity. In line with our observations, OC 
reactivity correlated with onset and severity of AD in human brain samples [39], and 
synaptotoxic oligomers of Aβ that interact with PrP and inhibit LTP were also recognised by OC 
[40]. 
 
Previous studies of colocalization of proteins within synapses were hampered by the difficulty of 
techniques such as immunogold EM, which are very low throughput and only allow one or two 
proteins of interest to be studied.  Here we used the relatively high-throughput array tomography 
technique [14] which allowed us to examine the colocalization of four antibodies within the same 
pre and postsynaptic terminals. Array tomography is limited by the reliance on antibody staining 
of synaptic proteins and threshold-based image analyses, which does not guarantee accurate 
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identification of synaptic puncta due to a combination of antibody specificity and analysis 
artifacts; however, a recent study using correlative array tomography and electron microscopy 
confirmed that ~98% of synapses in CA1 were accurately identified with array tomography 
staining [41]. This powerful technique will be useful since passive immunization with oAβ-specific 
antibodies is a promising potential treatment in AD, which could specifically reduce synaptic oAβ 
and reverse or prevent synapse loss.  With multiple oAβ-specific antibodies being developed 
[42-45], it will be crucial to find effective ways to quickly validate these antibodies in brain tissue, 
without extensive manipulation of brain samples. Conventional methods such as IP-western 
blotting and size exclusion chromatography required brain tissue to be homogenized, sonicated, 
and solubilized with different buffer solutions, making it difficult to ascertain whether such 
extensive sample manipulation introduces artificial Aβ conformers in the sample.  
 
Interestingly, we observe that the four antibodies tested with array tomography all recognized 
some synaptic Aβ but not at all of the same synapses. While there was some co-localization of 
two markers in the same synapses, this was at most half of the synapses that were labeled by 
only one of the antibodies, and synapses with 3 or all 4 of the markers were rare.  Post-hoc 
statistical comparisons between single, double and triple-labeling combinations indicated 
significantly fewer multiple stained synapses in many of the staining combinations (data not 
shown). There are limitations to the array tomography technique in both the staining (antibody 
penetration and affinity) and image analysis (filtering steps to remove noise) making it likely that 
we did not detect all of the positive synapses for each marker, however the reduced double and 
further reduced triple labeling across all combinations of antibodies indicates that there are 
distinct species of Aβ present at different synapses.  We expected that the pan- Aβ antibody 
AW7 would recognize the most synapses and would usually be present with all of the other 
markers, but this was not the case. It is possible that the fixation procedure or LR-White resin 
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embedding may affect the Aβ epitopes recognised by AW7. Alternatively, this could potentially 
be due to the relatively high affinity for AW7 staining fibrils. All antibodies tested labeled the 
plaque core to some extent, but AW7 stained fibrils very strongly. We postulate that if the 
antibodies have a high affinity for fibrils, they may have less opportunity to bind the less 
abundant synaptic Aβ, and the lower intensity synaptic staining may be below the detection level 
due to the bright staining of the fibrils in the same microscopic field.  
 
Another important observation in this study is the association of Aβ with both pre and 
postsynaptic elements.  Many of the studies of the synaptic effects of Aβ implicate postsynaptic 
mechanisms in synapse toxicity, but presynaptic mechanisms have also been found [27, 46].  
Our data show more Aβ at excitatory postsynapses than at presynaptic terminals consistent with 
the ideas that both pre and postsynapses are affected by Aβ and that postsynaptic processes 
are particularly important in synapse loss. Our data indicate that there is not likely a single 
synaptotoxic species of Aβ but instead multiple conformers are present inside pre and 
postsynaptic terminals near plaques. It is clear that Aβ-induced synaptic toxicity plays a major 
role in the pathogenesis of AD and that targeting synaptic pathology aiming at protecting or 
reversing synaptic damage is a promising avenue for developing disease-modifying treatments.  
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Table 1: Summary of antibody details for all experimental techniques 
Primary antibody Source Dilution  Working 
concentration 
(mg/ml) 
Secondary antibody 
FRET  
NAB61 Courtesy V Lee 1:25 0.107 Donkey anti-mouse Cy5 
(acceptor) 
PSD95 Abcam 
(ab12093) 
1:50 0.020 Donkey anti-goat Alexa 
Cy3 (donor) 
Immunogold TEM  
NAB61  Courtesy V Lee 1:20 0.134 immunogold-conjugated 
donkey anti-mouse 15nm 
gold conjugate 
STORM  
NAB61 Courtesy V Lee 1:20 0.134 Goat anti-mouse antibody 
(Jackson) labeled with 
Cy3 (activator 
dye)/Alexa647 (reporter 
dye)  
PSD95 Abcam 
(ab12093) 
1:50 0.020 Donkey anti-goat Alexa 
488 Invitrogen  
Array Tomography  
NAB61 Courtesy V Lee 1:200 0.013 Donkey anti-mouse 
Alexa594, Invitrogen 
1C22 D Walsh 1:25 0.040 Donkey anti-mouse 
Alexa488, Invitrogen 
OC Courtesy C 
Glabe 
1:50 polyclonal Donkey anti-rabbit 
Alexa647, Invitrogen 
AW7 D Walsh 1:500 polyclonal  Donkey anti-rabbit 
Alexa594, Invitrogen 
PSD95 Abcam 
(ab12093) 
1:50 0.020 Donkey anti-goat 
Alexa488 (day1), Alexa 
594 (day 2), Invitrogen  
Synaptophysin Abcam 
(ab8049) 
1:25 0.040 Donkey anti-mouse 
Alexa488, Invitrogen 
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Figure 1. Confirmation of oAβ  inside postsynaptic densities with STORM and TEM. 
STORM imaging of oligomeric Aβ labeled with NAB61 (A) shows the increased resolution of 
STORM compared to epifluorescence (epi). Overlaying the NAB61 STORM image with PSD95 
fluorescence (B) shows small oAβ punctae labeling synapses in the vicinity of plaques (arrow). 
Immunogold-TEM for NAB61 (C) shows 15 nm gold labeling of plaque fibrils (white arrows).  
NAB61 is also observed in a subset of postsynapses (black arrow) and presynaptic terminals 
(arrowheads).  Filaments were not observed in the synapses labeled with NAB61 indicating that 
a non-filamentous form of Aβ is present at synapses. Scale bars represent 5 µm in A, 1 µm in B, 
and 500 nm in C. 
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Figure 2. FRET analysis suggests that oAβ  is present within the postsynaptic density.   
FRET imaging was carried out on samples stained with PSD95 labeled with a Cy3 donor 
secondary antibody and NAB61 labeled with a Cy5 acceptor antibody.  The intensity of the Cy3 
labeling in synapses positive for NAB61 (arrow) increased after photobleaching the acceptor (A), 
indicating that NAB61 and PSD95 are within 10-30 nm of each other allowing non-radiative 
energy transfer between the donor and acceptor fluorophores before bleaching.  The FRET 
efficiency, plotted with a color map where red and yellow represent higher FRET efficiency, 
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shows increased FRET in synapses positive for oAβ (arrow, B).  Two-way ANOVA comparing 
NAB+ and NAB- synapses in APP/PS1 and wild-type mice reveal an increased FRET efficiency 
in NAB+ synapses indicating a close association between PSD95 and NAB61 (C). * p<0.05 
ANOVA. Scale bar represents 2 µm.  
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Figure 3. Array tomography experimental outline. Array tomography (three day process) was 
performed on ribbons of 70 nm thick sections of mouse brain tissue blocks in order to 
sequentially label oAβ and synaptic proteins as illustrated.  A tilescan was acquired of the DAPI 
staining (grey) at 10x magnification along the entire ribbon. The nuclear pattern was used to 
ensure the same region was imaged each day and to allow alignment of stacks between days 
(insets). 
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Figure 4. Array tomography staining of different anti-Aβ  antibodies in brain tissue. NAB61 
(A), 1C22 (B), OC (C) and AW7 (D) were used to label Aβ species, and synaptophysin (E) and 
PSD95 (F) were used to label pre- and post-synapses in APP/PS1 mouse tissue.  A three-
dimensional reconstruction of all merged channels is shown in (G) with inset (zoom in on dotted 
box) demonstrating the ability to resolve single synapses (arrow). Scale bars represent 10 µm in 
individual images and merged image (A-G) and 2 µm in the inset in (G).  
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Figure 5. Array tomographic colocalization of anti-Aβ  antibodies with pre- and post-
synapses in APP/PS1 tissue. Examples of array tomography images that have been 
processed (thresholded, filtered for single-section objects, i) and raw (ii) array tomography 
images of APP/PS1 tissue showing the colocalization of Aβ detecting antibodies with pre- 
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(arrowheads) and post- (arrows) synapses. Left panels show single 70 nm thick sections and far 
right panels show a three-dimensional reconstruction of 3 consecutive serial sections. Panel A) 
shows pre and post-synaptic punctae without Aβ staining. B) shows a post-synapse labelled with 
all four tested Aβ antibodies. C) shows a pre-synapse labelled with 1C22 and a post-synapse 
labelled with AW7 and D) shows PSD staining colocalizing with OC, AW7, and 1C22.  Scale bar 
represents 1 µm. 
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Figure 6. Multiple antibodies confirm the presence of oligomeric Aβ  assemblies at pre- 
and post-synapses. Quantification of the three-day array tomography staining paradigm 
reveals partially overlapping populations of pre and postsynaptic terminals stained with the four 
anti-Aβ antibodies used.  Venn diagrams (A) show the percentage of synapses stained with a 
single marker and approximate the overlap between the stains.  The precise amount of co-
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staining with each combination of antibodies is shown for post- (B) and pre-synaptic (C) 
terminals.  Medians and interquartile ranges across all mice are shown.  
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Supplemental Figures: 
 
 
Supplemental Figure 1. Robust NAB61 staining around plaque fibrils. NAB61 immunogold 
labeling (black dots) is shown in association with plaque fibrils in APP/PS1 mouse brain. Arrow 
points to NAB61 staining at the PSD of a synapse. Scale bar represents 500 nm. 
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Supplemental Figure 2. Oligomeric Aβ  staining was observed in structures other than 
plaques and synapses.  Arrows show immunogold labeling of NAB61 in mitochondria (A), 
neuronal somatic cytoplasm associated with rough endoplasmic reticulum (B), and in dendrites 
(C and D). Scale bar represents 500 nm. 
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Supplemental Figure 3. Antibody stripping removes synaptic and plaque labeling. Short 
ribbons of sections were used to confirm stripping efficacy in each experiment. Panel A shows 
postsynaptic staining with PSD95 and plaque staining with NAB61 on day 1. Panel B is the 
same area of the section after stripping and re-probing with secondary antibody (no primary). 
Similarly plaque staining on Day 2 with 1C22 and OC and postsynaptic staining with PSD95 
(Panel C) is completely absent after stripping and re-probing with secondary antibodies on Day 3 
(Panel D).  Scale bar represents 10 µm. 
 
 
  
